Resistant microbial infections have developed into one of our most serious health threats, affecting over two million people every year in the US with at least 23,000 dying as a result.  Although the medical need is urgent and often unmet; unique scientific bottlenecks, a complex regulatory environment, and relatively low return on investment compared to other therapeutic areas have led to an exodus of pharmaceutical development of new antibacterial agents.  To address these challenges the <i>IMI</i> (Innovative Medicines Initiative), launched the ND4BB (New Drugs for Bad Bugs) program creating a synergistic Public-Private-Partnership (PPP)-based approach encompassing all aspects of discovery to clinical development of new antibiotics. The ENABLE sub-subsection of ND4BB focuses on early discovery efforts for the identification of novel antibacterial agents. ENABLE has resources to fund up to six Hit-to-Lead or Lead optimization programs in parallel targeting the systemic treatment of infections due to resistant Gram-negative bacterial pathogens E. coli, K. pneumoniae, P. aeruginosa and A. baumannii.  The GSK-Sanofi alliance comprises one of these research efforts.<br/>

ENABLE(ing) drug discovery:  A public private partnership addressing antimicrobial resistance in serious gram negative infections

249th National Meeting (2015)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.